Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with neoadjuvant chemoradiotherapy before esophagectomy in locally advanced esophageal squamous cell carcinoma
ChiCTR2000031228Phase 4Not yet recruiting
- Sponsor
- Department of Thoracic Surgery, Medical Center of Amry Medical University
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Department of Thoracic Surgery, Medical Center of Amry Medical University. Primary endpoint: surgical rate. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000031228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031228.